Fig. 1
gCpG inhibits tumor growth and promotes T cell responses in primary tumor model. The levels of CD86 (a) and MHC II (b) expression on BMDC were measured by flow cytometry. c Tumor growth of melanoma-bearing mice. Mice were injected with 2 × 105 B16-OVA cells, and immunized s.c. with one of the three tumor vaccines at the left flank on day 7 and 12 post tumor inoculation, respectively. d Mice were sacrificed on day 19 after tumor inoculation. Percentage of tumor-infiltrating CD8+ T cells were analyzed by flow cytometry. e Tetramer staining of OVA–specific CD8+ T cells in TILs. Cytotoxicity assay of splenic CD8+ T cells (f) and other population without CD8+ T cells (g) from the tumor-bearing mice against B16-OVA tumor cells. The specific killings were determined using CytoTox 96 nonradioactive cytotoxicity assay. The data shown are the representative of at least three experiments. *p < 0.05 and **p < 0.01, ***p < 0.001 and ****p < 0.0001